Insights

What’s going on with the Australian Clinical Labs (ASX:ACL) share price lately?

Here’s what’s been driving the company’s stock this month
The post What’s going on with the Australian Clinical Labs (ASX:ACL) share price lately? appeared first on The Motley Fool Australia. –

The Australian Clinical Labs Ltd (ASX: ACL) share price is tumbling today, but it’s had a whopping run lately.

At the time of writing, the Australian Clinical Labs share price is $5.87. That’s 1.51% lower than its previous close but 38% higher than it was at the end of last month.

Additionally, it reached a new 52-week high in yesterday’s session, hitting $6.39 in intraday trade.

Let’s take a look at what’s been driving the company’s stock lately.

Australian Clinical Labs share price soars in December

Australian Clinical Labs’ stock took off last week after the company upgraded its guidance for the first half of financial year 2022 (FY22).

It now expects to bring in between $497.3 million and $517.2 million of revenue and net profits after tax of $116.3 million to $128 million.

The boosted expectations followed continuous strong demand for COVID-19 testing, particularly in New South Wales and Victoria. The company’s revenue is also being helped along by the resilience of its non-COVID business.

The company’s CEO Melinda McGrath commented on the company’s new outlook, saying:

We anticipate heightened volumes of COVID-19 testing to continue during the remainder of FY22 due to the impact of new variants and outbreaks, the lifting of travel restrictions and increased demand for both commercial and travel testing.

Thus, this week’s case numbers might have brought the stock some extra attention.

Over the 7 days to 8pm last night, New South Wales had reported 52,775 new cases of COVID-19. Of those, 12,226 were recorded in the previous 24 hours.

Victoria also announced a new record number of new daily cases today, with 5,137 of the state’s residents testing positive for the virus.

While the month so far has been a good one for the Australian Clinical Labs share price, today seems to be telling a different story. The company’s stock is tumbling for no obvious reason this morning.

However, despite the slump, it’s still in the long-term green. Right now, the Australian Clinical Labs share price is 72% higher than it was at the start of 2021.

Additionally, it isn’t alone in its recent gains. Fellow pathology companies, Healius Ltd (ASX: HLS) and Sonic Healthcare Limited (ASX: SHL) have seen their share prices increase 13% and 9% respectively this month.

The post What’s going on with the Australian Clinical Labs (ASX:ACL) share price lately? appeared first on The Motley Fool Australia.

Should you invest $1,000 in Australian Clinical Labs right now?

Before you consider Australian Clinical Labs, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Australian Clinical Labs wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Brokers name 3 ASX shares to buy today

Why Australian Clinical Labs, Magellan, Sandfire, and Telix shares are rising

Why the Australian Clinical Labs (ASX:ACL) share price is up 10% to a record high

Why Australian Clinical Labs, Humm, Neometals, and Viva Energy are rising

Analysts are tipping huge gains for these small cap ASX shares

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Australian Clinical Labs Limited and Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!